Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2025-07-17 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于2025年半年度业绩预告的自愿性披露公告
Earnings Release Classification · 95% confidence The document is a voluntary disclosure announcement regarding the company's forecasted financial performance for the half-year period ending June 30, 2025. It provides preliminary estimated financial figures such as revenue and net profit, explicitly states that the forecast is unaudited, and mentions that the final official financial data will be disclosed in the formal half-year report. The document length is short (986 characters) and it does not contain actual financial statements or detailed analysis, only preliminary forecast data. This fits the profile of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results highlighting key figures and outlook before the formal report is published. H1 2025
2025-07-17 Chinese
自愿披露关于西达本胺一线治疗弥漫大B细胞淋巴瘤的III期临床试验获得顶线分析数据的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shenzhen Microchip Biotech Co., Ltd. regarding the top-line analysis data of a Phase III clinical trial for a drug (chidamide) treating diffuse large B-cell lymphoma (DLBCL). It provides detailed clinical trial results, drug mechanism, and regulatory approval status. The document is an announcement of clinical trial results and regulatory updates rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. It is not a regulatory filing about corporate governance, board changes, or shareholding. The document is relatively short (2040 characters) and serves as a public announcement of clinical trial data and related regulatory progress. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-09 Chinese
关于《深圳微芯生物科技股份有限公司股票交易异常波动问询函》的回函
Regulatory Filings Classification · 95% confidence The document is a formal reply letter to an inquiry about abnormal stock trading fluctuations. It addresses the absence of undisclosed material information, ongoing major corporate actions, and stock transactions by the controlling shareholder during the period of abnormal trading. The content is regulatory in nature, related to compliance and disclosure, but does not contain financial statements, audit results, or detailed financial data. It is a regulatory response letter rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and it is a direct reply to a regulatory inquiry, confirming no undisclosed material events or insider trading.
2025-07-03 Chinese
股票异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding abnormal stock price fluctuations over three consecutive trading days, with a cumulative price increase of 30%. It includes the company's investigation results, confirming no undisclosed material information, and reminds investors to be cautious. The document references stock exchange trading rules and regulatory requirements for disclosure. It does not contain financial statements, detailed financial data, or management discussion of results. It is a regulatory announcement about stock price behavior and compliance with disclosure rules, typical of a Regulatory Filings (RNS) category. The document length is short (1755 characters), and it is not a report or presentation but a compliance announcement.
2025-07-03 Chinese
自愿披露关于CS231295临床试验申请获得FDA受理的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shenzhen Microcore Biotech Co., Ltd. regarding the acceptance of a clinical trial application (CS231295) by the FDA. It contains no financial data, no financial statements, and no detailed financial analysis. It is an announcement about a regulatory milestone related to drug development, not a financial report or earnings release. The document is short (1120 characters) and serves as a formal public notice of the FDA acceptance of the clinical trial application. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-01 Chinese
关于可转债转股结果暨股份变动的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the results of convertible bond conversions and related share capital changes for Shenzhen Microchip Biotechnology Co., Ltd. It details the amount of convertible bonds converted into shares during a specific quarter and cumulatively, as well as the remaining unconverted bonds. It also provides background on the bond issuance and conversion terms. The document is relatively short (1787 characters) and focuses on reporting the conversion results and share capital changes rather than providing a full financial report or detailed analysis. This type of document fits the category of Capital/Financing Update (CAP), as it updates on the company's financing activities related to convertible bonds and share capital changes.
2025-07-01 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.